Choi, YK, Adham, N, Kiss, B, Gyertyán, I, Tarazi, FI. Long-term effects of cariprazine exposure on dopamine receptor subtypes. CNS Spectr 2014;19(3):268–77.CrossRefGoogle ScholarPubMed

Citrome, L. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy. Adv Ther 2013;30(2):114–26.Google ScholarPubMed

Earley, WR, Burgess, MV, Khan, B, et al. Efficacy and safety of cariprazine in bipolar I depression: a double-blind, placebo-controlled phase 3 study. Bipolar Disord 2020;22(4):372–84. doi: 10.1111/bdi.12852.CrossRefGoogle Scholar

Huhn, M, Nikolakopoulou, A, Schneider-Thoma, J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 2019;394:939–51.CrossRefGoogle ScholarPubMed

McIntyre, RS, Suppes, T, Earley, W, Patel, M, Stahl, SM. Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies. CNS Spectr 2019;1–9. doi:10.1017/S1092852919001287.CrossRefGoogle Scholar

Stahl, SM, Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes, CNS Spectr 2017;22:375–84.CrossRefGoogle Scholar

Stahl, SM, Laredo, S, Morrissette, DA. Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data. Ther Adv Psychopharmacol 2020;10:2045125320905752. doi: 10.1177/2045125320905752. eCollection 2020.CrossRefGoogle ScholarPubMed

Vieta, E, Durgam, S, Lu, K, et al. Effect of cariprazine across the symptoms of mania in bipolar I disorder: analyses of pooled data from phase II/III trials. Eur Neuropsychopharmacol 2015;25(11):1882–91.CrossRefGoogle ScholarPubMed

Vieta, E, Earley, WR, Burgess, MV, et al. Longterm safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder. Int Clin Psychopharmacol 2019;34(2):76–83.CrossRefGoogle Scholar